Bioextrax AB (SE:BIOEX)
:BIOEX
Want to see SE:BIOEX full AI Analyst Report?
BIOEX Stock Chart & Stats
kr3.19
kr0.10(3.70%)
At close: 4:00 PM EST
kr3.19
kr0.10(3.70%)
Day’s Range― - ―
52-Week Rangekr1.60 - kr3.98
Previous CloseN/A
Volume15.49K
Average Volume (3M)82.14K
Market Cap
kr120.43M
Enterprise Valuekr87.92M
Total Cash (Recent Filing)kr3.93M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Aug 21, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding47,601,730
10 Day Avg. Volume104,394
30 Day Avg. Volume82,137
Financial Highlights & Ratios
PEG Ratio0.47
Price to Book (P/B)5.23
Price to Sales (P/S)146.53
P/FCF Ratio-4.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.37
Revenue Forecast (FY)kr2.34M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA zero-debt, conservatively financed balance sheet materially reduces refinancing and interest-rate risk over the medium term. This structural strength provides the company optionality to fund R&D or commercial ramp via equity or partnerships rather than servicing debt, helping preserve cash runway during development cycles.
Diversified Commercialization PathwaysBioextrax's business model supports multiple durable revenue channels—product sales, licensing, and fee-for-service development—which can scale differently and diversify risk. Licensing and service contracts offer higher-margin, recurring or milestone-based cash inflows if technology adoption grows, improving long-term cash visibility.
Structural Industry TailwindsThe firm operates in industrial biotech and biorefinery markets aligned with sustainability and circular-economy trends. Demand for bio-based ingredients and valorizing side streams is a durable structural trend driven by regulation and corporate ESG goals, supporting long-run addressable market expansion for proven process technologies.
Bears Say
Negative Unit EconomicsPersistent negative gross margins indicate core unit economics are not yet viable at current scale. Structural negative gross profit forces dependency on cost cuts, process improvements, or higher pricing to reach sustainable profitability; absent that, scaling revenues will not translate into positive operating results over time.
Consistent Cash BurnRepeated negative operating and free cash flow with accelerating burn in 2025 creates a durable financing overhang. The business cannot self-fund growth, increasing the probability of dilution or constrained investment in commercialization until unit economics improve or strategic funding is secured.
Very Small, Declining RevenueSmall, volatile and declining revenue limits ability to absorb fixed costs or demonstrate repeatable commercial traction. Continued revenue shrinkage alongside ongoing losses erodes equity and constrains reinvestment, making it harder to achieve scale economies necessary for long-term margin recovery.
BIOEX FAQ
What was Bioextrax AB’s price range in the past 12 months?
Bioextrax AB lowest stock price was kr1.60 and its highest was kr3.98 in the past 12 months.
What is Bioextrax AB’s market cap?
Bioextrax AB’s market cap is kr120.43M.
When is Bioextrax AB’s upcoming earnings report date?
Bioextrax AB’s upcoming earnings report date is Aug 21, 2026 which is in 70 days.
How were Bioextrax AB’s earnings last quarter?
Bioextrax AB released its earnings results on May 20, 2026. The company reported -kr0.09 earnings per share for the quarter, beating the consensus estimate of -kr0.1 by kr0.01.
Is Bioextrax AB overvalued?
According to Wall Street analysts Bioextrax AB’s price is currently Overvalued.
Does Bioextrax AB pay dividends?
Bioextrax AB does not currently pay dividends.
What is Bioextrax AB’s EPS estimate?
Bioextrax AB’s EPS estimate is -0.09.
How many shares outstanding does Bioextrax AB have?
Bioextrax AB has 47,601,730 shares outstanding.
What happened to Bioextrax AB’s price movement after its last earnings report?
Bioextrax AB reported an EPS of -kr0.09 in its last earnings report, beating expectations of -kr0.1. Following the earnings report the stock price went up 11.2%.
Which hedge fund is a major shareholder of Bioextrax AB?
Currently, no hedge funds are holding shares in SE:BIOEX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bioextrax AB
Bioextrax AB (publ) focuses on developing and commercializing a groundbreaking, biology-driven extraction system. This advanced technology facilitates the recovery of a variety of valuable materials from bacterial origins, such as bioplastic granules (PHA), organic hydrolyzed proteins, keratin fibers, different bio-oils, protein-rich co-products, and amino acids. The firm was founded in 2014 and conducts its operations from Lund, Sweden.
Technical Analysis
Scandinavian Enviro Systems AB
―
Axolot Solutions Holding AB
―
Nordic LEVEL Group AB Class B
―
CirChem AB
―
Clemondo Group AB
―